be_ixf;ym_202104 d_12; ct_100

Select Page

COVID-19 Testing Just Got 3 Huge Upgrades

COVID-19 Testing Just Got 3 Huge Upgrades

It turns out that getting tested for COVID-19 is a bigger hassle than it seems.

I have a medical procedure coming up, and my doctor required me to take a COVID-19 test even though I felt fine.

The first time I went to the urgent care office to get tested, the computer network was down, so they couldn’t enter my information and give me a test.

I came back the next day. And after waiting for an entire hour and answering a bunch of questions, I finally got what I came there for: a long swab jammed far back up my nose.


Overall, I’d say my experience wasn’t great … although, at least my results came back negative.

But thanks to a few innovative medical companies, COVID-19 testing is getting cheaper, faster and more convenient.


Upgrade No. 1: At-Home Tests

Picture Genetics, based in Temple City, California, is a division of Fulgent Genetics Inc. (Nasdaq: FLGT).

In June, the company received Food and Drug Administration (FDA) approval for its at-home COVID-19 test.

For $119, you can order a test in the mail. You then send your nasal swab back to Picture in a pre-labeled envelope, and it will email you your results in three to four days.

Thanks to a few innovative medical companies, COVID-19 testing is getting cheaper, faster and more convenient.

(Source: Picture Genetics)

Picture can test up to 30,000 samples a day. However, it’s currently expanding to a second, larger location, which will allow it to test a total of 90,000 samples a day.


Upgrade No. 2: Saliva Tests

Fluidigm Corp. (Nasdaq: FLDM) worked on a saliva-based COVID-19 test with the Washington University School of Medicine in St. Louis.

The FDA approved its test on Tuesday. That gives people an easy and inexpensive option to just take a saliva sample — no uncomfortable nasal swabs needed.

Thanks to a few innovative medical companies, COVID-19 testing is getting cheaper, faster and more convenient.

(Source: Ingram’s)

According to Fluidigm CEO Chris Linthwaite: “We have a high degree of confidence that this new test will not only enhance testing capacity but will also significantly improve speed to results and scale.”


Upgrade No. 3: 15-Minute Tests

Perhaps the biggest new development for COVID-19 is a 15-minute test from Abbott Laboratories (NYSE: ABT).

The test just got FDA approval on Wednesday. President Donald Trump then announced a $750 million deal with Abbott at the Republican National Convention on Thursday night.

The test uses a nasal swab and is the size of a credit card. Best of all, it only costs $5.

Thanks to a few innovative medical companies, COVID-19 testing is getting cheaper, faster and more convenient.

(Source: Abbott)

Abbott’s Navica mobile app also makes accessing results quick and easy.

The Trump administration ordered 150 million of these tests. Abbott plans to start shipping them as early as next month before ramping up production in October.


More Innovations Are Ahead

What’s really amazing is that two of the companies I highlighted above — Fulgent and Fluidigm — are tiny.

Fulgent is just a $654 million company, and Fluidigm is only worth $592 million.

And there are many other small but innovative companies doing remarkable things today, whether it’s in biotech, the Internet of Things, virtual reality or other exciting tech fields.

These stocks aren’t like the Amazons, Netflixes or Apples of the world — those are the stocks of yesteryear.

Rather, small-cap companies are the next generation of massive winners. And they’re poised to return exponential growth to investors’ portfolios.

Next month, my colleague Ian King will have an incredible presentation for you highlighting some of the biggest opportunities in small companies like these.

You won’t want to miss it!


Jay Goldberg

Assistant Managing Editor, Banyan Hill Publishing

Newsletter Sign Up




“Paul, your investment research has been a godsend. Our portfolio was just a tad over two million dollars. I paid my daughter's legal fees, my wife's medical expenses, helped my wife's stepmother with home repairs, loaned our son money for real estate. I also bought two used vehicles, one for our daughter and one for our eldest grandson. All told, these expenses added up to well over a quarter million dollars. I am happy to report that we have profits left over!”

- Taylor M.

"You have done once again!! You are reminding me of the GREAT Joe DiMaggio with your consistent hitting!! You knocked this one out of the park!"

- Keith S.

"I went all in with $310,000 and a year later, my portfolio was at $425,000. This I would have never accomplished with mutual funds, I will be following your research for the rest of my life thank you Paul and the team."

- Karl A.

Share This